{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:51:23Z","timestamp":1792623083294,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Alpha-blockers (ABs) are commonly prescribed as part of a multidrug regimen in the management of hypertension. We set out to assess the risk of hypotension and related adverse events with AB use compared with other blood pressure (BP) lowering drugs using a population-based, retrospective cohort study of women (\u226566 years) between 1995 and 2015 in Ontario, Canada. Cox proportional hazards examined the association of AB use and hypotension and related events (syncope, fall, and fracture) compared with other BP lowering drugs matched via a high dimensional propensity score. The primary outcome was a composite of hospitalizations for hypotension and related events (syncope, fractures, and falls) within 1 year. From 734\u2009907 eligible women, 14\u2009106 were dispensed an AB (mean age, 75.7; standard deviation 6.9 years, median follow-up 1 year) and matched to 14\u2009106 dispensed other BP lowering agents. The crude incidence rate of hypotension and related events was 95.7 (95% CI [confidence interval], 90.4\u2013101.1, events 1214 [8.6%]) with AB and 79.8 (95% CI, 74.9\u201384.7 per 1000 person-years, events 1025 [7.3%]) with other BP lowering medications (incident rate ratio, 1.20; 95% CI, 1.10\u20131.30). The risk was higher for hypotension (hazard ratio, 1.71; 95% CI, 1.33\u20132.20) and syncope (hazard ratio, 1.44; 95% CI, 1.18\u20131.75) with no difference in falls, fractures, adverse cardiac events, or all-cause mortality. Treatment of hypertension in women with ABs is associated with a higher risk of hypotension and hypotension-related events compared with other BP lowering agents. Our findings suggest that ABs should be used with caution, even as add on therapy for hypertension.<\/jats:p>","DOI":"10.1161\/hypertensionaha.119.13289","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T09:00:31Z","timestamp":1563786031000},"page":"645-651","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age"],"prefix":"10.1161","volume":"74","author":[{"given":"Swapnil","family":"Hiremath","sequence":"first","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Petrcich","sequence":"additional","affiliation":[{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"McCallum","sequence":"additional","affiliation":[{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Hundemer","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tanuseputro","sequence":"additional","affiliation":[{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Manuel","sequence":"additional","affiliation":[{"name":"Kidney Research Centre, Ottawa Hospital Research Institute (D.M., K.B.), University of Ottawa, Canada"},{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Burns","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"},{"name":"Kidney Research Centre, Ottawa Hospital Research Institute (D.M., K.B.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Edwards","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Bugeja","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Magner","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"},{"name":"Bruyere Research Institute, the Ottawa Hospital, Canada (P.T.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"McCormick","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"},{"name":"Division of Nephrology, Western University, London, Canada (A.X.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rhodes","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology, The Ottawa Hospital (S.H., M.R., G.L.H., K.B., C.E., A.B., P.M., B.M., E.R., M.M.S.), University of Ottawa, Canada"},{"name":"The Institute of Clinical Evaluative Sciences, ON, Canada (W.P., M.K.M., P.T., D.M., A.X.G., M.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19043"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.03.005"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606123142404"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.05300.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.1967"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5398"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2003.01227.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1402"},{"key":"e_1_3_4_12_2","first-page":"CD004643","article-title":"Blood pressure lowering efficacy of alpha blockers for primary hypertension.","author":"Heran BS","year":"2012","unstructured":"Heran, BS, Galm, BP, Wright, JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012:CD004643.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_13_2","unstructured":"Statistics Canada. Population by year by province and territory (number). 2012. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501. Accessed October 22 2018."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00018-6"},{"key":"e_1_3_4_16_2","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.","volume":"10","author":"Levy AR","year":"2003","unstructured":"Levy, AR, O\u2019Brien, BJ, Sellors, C, Grootendorst, P, Willison, D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67\u201371.","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0119-1"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1162\/003465302317331982"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"e_1_3_4_21_2","first-page":"63","volume-title":"In: Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell FE","year":"2015","unstructured":"Harrell, FE. Multivariable modeling strategies. In: Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Cham, Switzerland: Springer International Publishing; 2015:63\u2013102."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07474"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2016.1236329"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-33"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(17)34072-X"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.13289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:19:20Z","timestamp":1715595560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.119.13289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.119.13289"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.119.13289","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}